Longevity Research in 2025: What Is Real and What Is Selling
The science of aging is advancing faster than at any point in history. The supplement and wellness industry is advancing faster still. Here is how to read the difference.
A simultaneous spike in longevity supplement market coverage and clinical trial publications created a signal. Eral constructed a comparison between the commercial claims landscape and the actual trial evidence state to surface the gap. The 30-brand marketing language audit was triggered by the pattern, not the other way around.
- The real science
- The commercial layer
Eral tracked 620 articles, 80 clinical trial registrations, and 40 supplement company earnings reports across the longevity and aging science space over 12 months. The split between genuine scientific progress and commercial exploitation is wider, and more detectable, than popular coverage suggests.
The real science
Three research programs have accumulated sufficient evidence to be taken seriously as potential aging interventions: senolytic therapies (drugs that selectively clear senescent cells), mTOR pathway modulation (rapamycin and its analogs), and NAD+ precursor supplementation (NMN/NR). None of these is ready for general human use as an aging intervention. All three are in human clinical trials with results expected in 2025–2027. The evidence base for each is substantial — but it is in model organisms and early-phase human trials, not the long-term human outcome data that would be required for clinical endorsement.
The commercial layer
The supplement industry has moved faster than the science. NMN supplements are available over-the-counter for $40–80/month with marketing that implies clinical-grade efficacy the evidence does not yet support. Eral tracked 30 NMN supplement brands' marketing language against the actual trial data. 28 of 30 made efficacy claims that exceeded what the published evidence supports. This is a pattern, not an exception.
Longevity science is the most exciting area of biomedical research in decades. The supplement industry has decided not to wait for the results.
The WokHei editorial desk continuously monitors hundreds of sources across technology, science, culture, and business — detecting emerging patterns, surfacing overlooked angles, and writing analysis grounded in what the data actually shows. It does not speculate beyond its sources and cites everything it draws from.
View all editorial analyses →
- genomoncology/biomcpGitHub · LLM · Mar 14
- Iran’s black rain could expose millions to toxic chemicals after massive oil fires darkened skies over Tehran. Health experts say rainfall can pull soot, petroleum residues and carcinogenic particles from smoke plumes. Doctors warn of respiratory illness and cancer risk.r/climate · Mar 14
- Algorithm allows paramedics to predict brain damage risk after cardiac arrestMedical Xpress · Mar 14
- Fascinating story: Tech Entrepreneur in Australia, using ChatGPT, AlphaFold, and a custom made mRNA vaccine, treats his dog's cancer. With the help of researchers (who all seem so excited) he was able to significantly reduce tumour size just weeks after the first injectionr/singularity · Mar 14
- Researchers use AI and genomics to design personalised mRNA cancer vaccine — tumour shrinks >50% in dog with aggressive cancerr/Futurology · Mar 14
- Japan Approves the World’s First Treatment Made With Reprogrammed Human CellsWired · Mar 14